by Scientists feared the H5N1 virus could jump from birds to humans and trigger a pandemic - Click to enlarge Ten years ago Swiss pharmaceutical giant Novartis carried out clinical trials for a bird flu vaccine on homeless people in Poland. One man, who says they were told they were being tested for a conventional flu vaccine, is now suing the Basel-based company. When the H5N1 virus broke outexternal link among birds in Europe in 2005, scientists feared it could be transmitted from human to human and cause a pandemic. The pharmaceutical industry across Europe rushed to develop a vaccine. In 2007, Novartis tested a vaccine in a clinic in the Polish city of Grudziadz. The subjects – homeless and poor people – were
Topics:
Swissinfo.ch considers the following as important: Business, Featured, newslettersent, Swiss Markets and News
This could be interesting, too:
Frank Shostak writes Could an Increase in the Supply of Gold Cause a Boom-Bust Cycle?
Swissinfo writes How the poorest country in Europe is integrating 120,000 Ukrainian refugees
Vibhu Vikramaditya writes Liberty Squandered: The English Tradition from Magna Carta to Empire
Mark Thornton writes Gold Is the Answer to Prohibition
Scientists feared the H5N1 virus could jump from birds to humans and trigger a pandemic - Click to enlarge
Ten years ago Swiss pharmaceutical giant Novartis carried out clinical trials for a bird flu vaccine on homeless people in Poland. One man, who says they were told they were being tested for a conventional flu vaccine, is now suing the Basel-based company.
When the H5N1 virus broke outexternal link among birds in Europe in 2005, scientists feared it could be transmitted from human to human and cause a pandemic. The pharmaceutical industry across Europe rushed to develop a vaccine.
In 2007, Novartis tested a vaccine in a clinic in the Polish city of Grudziadz. The subjects – homeless and poor people – were reportedly paid around CHF2 ($2) to be tested on what they thought was a vaccine for normal flu.
Although no deaths have been directly proved as a result of the Novartis trial, the director of a homeless centre in Grudziadz told a Polish paper that in 2007 there were 21 deaths in the centre, compared with the average of about eight.
Now, one of the subjects, Grzegorz S., has launched a civil suit against Novartis.
“No one told us it was a test for a new drug. The whole time they said it was a completely normal vaccine for the normal flu,” he told 10vor10external link, a news programme on Swiss public television, SRF, on Wednesday.
‘Clearly liable’
The arbitration process took place in Basel at the beginning of July but no agreement was reached, Grzegorz S.’s lawyer told 10vor10.
Grzegorz S.’s is now suing Novartis for CHF50,000 in compensation and at least CHF50,000 of the profits generated by the vaccine.
The lawyer said Novartis, which had engaged a company based in Germany and Poland to carry out the trials, was clearly liable. “The sponsor of the tests – that is, whoever arranges them and receives the profits – must be responsible for the actions of their auxiliaries,” he said.
In a statement sent to swissinfo.ch, Novartis said: “The criminal proceedings of the case in Poland were concluded earlier this year with the conviction of the accused healthcare professionals for conducting clinical trials without proper consent of the subjects, and also for defrauding Novartis and another third party as to the veracity of the clinical trials.”
It added: “Novartis is pleased that this long-running criminal case in Poland has finally been concluded and that those who were guilty of fraudulent actions that may have put patients at risk have been brought to justice. We stress that while the criminal proceedings in Poland were comprehensive, Novartis was not under investigation at any time in connection with this case. Novartis is committed to the highest standards at all times and demands the same from external partners we work with.”
The company underlined that “all Novartis clinical trials adhere to the ethical values embodied in the Declaration of Helsinkiexternal link and Good Clinical Practiceexternal link, which safeguard the health and human rights of patients in clinical research”.
Regarding the civil case in Basel, Novartis said it did not comment on ongoing legal cases.
Tags: Business,Featured,newslettersent